Is Dare Bioscience, Inc. (DARE) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 6.0% / 30% | 71.8% / 30% | 1.1% / 30% | 198261.3% / 5% | ✗ NOT HALAL |
| DJIM | 6.0% / 33% | 71.8% / 33% | 1.1% / 33% | 198261.3% / 5% | ✗ NOT HALAL |
| MSCI | 5.9% / 33% | 71.0% / 33% | 1.0% / 33% | 198261.3% / 5% | ✗ NOT HALAL |
| S&P | 6.0% / 33% | 71.8% / 33% | 1.1% / 33% | 198261.3% / 5% | ✗ NOT HALAL |
| FTSE | 5.9% / 33% | 71.0% / 33% | 1.0% / 50% | 198261.3% / 5% | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | -162340.8% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -2543.1% | |
| Return on Assets (ROA) | -44.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | $5M |
| Free Cash Flow | $5M |
| Total Debt | $1M |
| Debt-to-Equity | 102.6 |
| Current Ratio | 1.2 |
| Total Assets | $22M |
Price & Trading
| Last Close | $1.51 |
| 50-Day MA | $1.66 |
| 200-Day MA | $2.04 |
| Avg Volume | 81K |
| Beta | 1.0 |
|
52-Week Range
$1.27
| |
About Dare Bioscience, Inc. (DARE)
Daré Bioscience, Inc. develops therapies in the areas of contraception, pelvic pain, fertility, infectious disease, menopause, and sexual and vaginal health in the United States. The company offers XACIATO, a lincosamide antibacterial gel for the treatment of bacterial vaginosis. It also develops Ovaprene, a hormone-free monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia for the treatment of female sexual arousal disorder; DARE-HRT1 to treat vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of dyspareunia or pain during sexual intercourse; and DARE-HPV, a fixed-dose formulation of lopinavir and ritonavir in a soft gel vaginal insert to treat genital human papillomavirus (HPV) infection, cervical intraepithelial neoplasia, and other HPV-related pathologies. In addition, the company develops DARE-PDM1, a hydrogel formulation of diclofenac for vaginal administration to treat primary dysmenorrhea; DARE-204 and DARE-214, injectable formulations of etonogestrel that provides contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. Further, it develops DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design controlled contraceptive option; DARE-RH1, an approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein; DARE-LBT, a vaginal thermosetting gel formulation for the delivery of live biotherapeutics; and DARE-GML, which delivers antimicrobial glycerol monolaurate intravaginally. Daré Bioscience, Inc. was founded in 2015 and is headquartered in San Diego, California.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Dare Bioscience, Inc. (DARE) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Dare Bioscience, Inc. is Not Halal. The company fails one or more screening criteria. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Dare Bioscience, Inc.'s debt ratio?
Dare Bioscience, Inc.'s debt ratio is 6.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 5.9%.
What are Dare Bioscience, Inc.'s key financial metrics?
Dare Bioscience, Inc. has a market capitalization of $23M, and revenue of $9,784. Return on equity stands at -2543.1%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.